ACE and amyotrophic lateral sclerosis: Compared to the ALS controls, a significantly larger proportion of the riluzole patients received cardioprotective agents during the baseline periods, including angiotensin‐converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), beta blockers, Ca2+ channel blockers (CCB), metformin, and anti‐lipid agents (Table 1).